Abstract

Simple SummaryChimeric antigen receptor (CAR) T cells have shown promising results in cancer treatment. They can be generated with T cells from patients for personalized therapy or donors for off-the-shelf products. A critical step in producing the allogeneic CAR T cells is to knock out the endogenous T cell receptor (TCR). The objective of this study is to determine if inhibition of caspase activities in T cells could increase the cell viability after the TCR knockout mediated by the electrotransfer technology. We observed that inhibition of caspases, especially caspase 3, could significantly improve the cell viability and electrotransfer efficiency. Treatment of cells with caspase inhibitors post electrotransfer could also improve the efficiency of TCR knockout in primary human T cells using electrotransferred ribonucleoprotein. Our data suggest that inhibition of caspases is a promising strategy for improving CAR T cell production.T cell receptor (TCR) knockout is a critical step in producing universal chimeric antigen receptor T cells for cancer immunotherapy. A promising approach to achieving the knockout is to deliver the CRISPR/Cas9 system into cells using electrotransfer technology. However, clinical applications of the technology are currently limited by the low cell viability. In this study, we attempt to solve the problem by screening small molecule drugs with an immortalized human T cell line, Jurkat clone E6-1, for inhibition of apoptosis. The study identifies a few caspase inhibitors that could be used to simultaneously enhance the cell viability and the efficiency of plasmid DNA electrotransfer. Additionally, we show that the enhancement could be achieved through knockdown of caspase 3 expression in siRNA treated cells, suggesting that the cell death in electrotransfer experiments was caused mainly by caspase 3-dependent apoptosis. Finally, we investigated if the caspase inhibitors could improve TCR gene-editing with electrotransferred ribonucleoprotein, a complex of Cas9 protein and a T cell receptor-α constant (TRAC)-targeting single guide RNA (sgRNA). Our data showed that inhibition of caspases post electrotransfer could significantly increase cell viability without compromising the TCR disruption efficiency. These new findings can be used to improve non-viral T cell engineering.

Highlights

  • Chimeric antigen receptor (CAR) T cell therapy has been approved to treat patients with variousB cell-related tumors, including B-cell precursor acute lymphoblastic leukemia (ALL), diffuse largeB-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and high-grade B-cell lymphoma [1]

  • We observed that the inhibition of apoptosis could significantly increase both the cell viability and electrotransfer efficiency

  • We identified z-vad-fmk to be the most potent inhibitor of cell death induced by electrotransfer (Figure S1)

Read more

Summary

Introduction

Chimeric antigen receptor (CAR) T cell therapy has been approved to treat patients with variousB cell-related tumors, including B-cell precursor acute lymphoblastic leukemia (ALL), diffuse largeB-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and high-grade B-cell lymphoma [1]. The autologous CAR T cells are patient-specific, but it is a challenge to produce them for a subpopulation of cancer patients, and the production platform is currently inefficient for large-scale clinical applications [4]. To avoid these problems, multiplexed genome editing strategies have been used to knock out certain endogenous genes, such as αβ T-cell receptor (TCR), in donor T cells to generate allogeneic universal CAR T cells [5,6], which can be produced massively and applied to treat a large number of patients [5]. One of the promising approaches to gene knockout is to deliver the CRISPR/Cas system into cells using electrotransfer technology [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call